Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI takes on IBD colonoscopy: could it outsmart a special light?

NCT ID NCT07694362

Disease control Sponsor: Vall d'Hebron Institute Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

People with inflammatory bowel disease (IBD) have a higher risk of colorectal cancer and need regular colonoscopies to catch early warning signs. This study compares two techniques—narrow-band imaging (a special light) and an artificial intelligence (AI) system—to see which finds more abnormal tissue during these exams. Each participant will have their colon examined twice in one session, once with each method, by different doctors. The goal is to determine whether AI, which is easier to use, can be a reliable alternative for cancer surveillance in IBD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence (AI) detection system (ENDO-AID CADe) and narrow-band imaging (NBI)
What this could lead to
If AI proves as good as or better than NBI, it could make cancer surveillance colonoscopies easier and more accessible for people with IBD.
What could go wrong
This is a small, single-center study with 60 participants. The AI tool was designed for people without IBD, so it may not perform as well in inflamed bowels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Jan 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with IBD, scheduled for endoscopic colorectal cancer surveillance following the ECCO guidelines. * ≥ 18 years-old. * At least 8 year duration ulcerative colitis (UC) or colonic Crohn's disease (CD) unless in case of concomitant primary sclerosing cholangitis which any disease duration was eligible for screening colonoscopy. Exclusion Criteria: * Inadequate bowel preparation (Boston Bowel Preparation Scale \< 6). * The presence of any degree of endoscopic inflammation or technical reasons that prevented completion of colonoscopy, such as a critical stenosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence (AI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon dysplasia Crohn disease Crohn's colitis inflammatory bowel disease neuroblastoma ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence (AI) Chromoendoscopy Colonic dysplasia/adenomata Crohn's disease colon Inflammatory bowel disease (Crohn&#39;S disease and ulcerative colitis) NBI Surveillance colonoscopy Ulcerative colitis (UC)

Contacts and locations

Locations

  • Vall d'Hebron University Hospital

    Barcelona, Catalonia, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.